

Stephan Grupp, MD, PhD
Medical Director
Cell and Gene Therapy Lab
Children's Hospital of Philadelphia

Stephan Grupp, MD PhD, is Chief of the Cellular Therapy and Transplant Section, Director of the Susan and Steven Kelly Center for Cancer Immunotherapy, and Medical Director of the Cell and Gene Therapy Lab at CHOP, as well as Novotny Professor of Pediatrics (with tenure) at U Penn's Perelman School of Medicine. He has authored over 250 articles and book chapters during his research career across the translational spectrum. He leads the largest pediatric cell therapy program in the country, a group which recently celebrated treating their 500th CAR T patient. Dr. Grupp came to CHOP in 1996 after receiving his MD/PhD in Cincinnati and doing his clinical training in Boston. His primary area of research is the use of CAR T and other engineered cell therapies in pediatric cancers and other life-threatening disorders such as sickle cell disease. He led all of the pediatric ALL trials of the CAR T product CTL019 (tisa-cel), including Novartis' international registration trial, leading to the first FDA approval of a CAR product (Kymriah). As a result of this work, he presented the Clinical Perspective at the first FDA ODAC CAR meeting. He is currently the Study Steering Committee Lead for the Vertex international registration trial of their CRISPR-edited product for sickle cell disease. Dr. Grupp was elected to the National Academy of Medicine in 2019.